M.D. Anderson Cancer Center: Precursor Cell Lymphoblastic Leukemia-Lymphoma trials

The registry lists 73 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies with M.D. Anderson Cancer Center as lead sponsor. 8 are open to participants now and 36 have results posted.

Phase 1 27Phase 2 54Phase 3 2No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• 2 Gy Total Body Irradiation As Part Of Conditioning Treatment For Patients With Acute Lymphoblastic Leukemia Undergoing CAR T Cell TherapyNot yet recruitingNCT07856758Not applicable
• A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic LeukemiaNot yet recruitingNCT07283640Phase 1
• Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)Not yet recruitingNCT07178912Phase 2
• Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL)RecruitingNCT07053059Phase 2
• Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaRecruitingNCT06308588Phase 1/2
• Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic LeukemiaRecruitingNCT03263572Phase 2
• Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/LeukemiaRecruitingNCT03136146Phase 2
• Personalized NK Cell Therapy in CBTRecruitingNCT02727803Phase 2
• Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBLTerminatedNCT05464836Phase 2Results posted
• Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaTerminatedNCT05032183Phase 1/2Results posted
• DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic LeukemiaTerminatedNCT04752163Phase 1/2Results posted
• Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell TransplantationTerminatedNCT03856216Phase 2Results posted
• Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous LeukemiaTerminatedNCT03576547Phase 1/2Results posted
• Levocarnitine and Vitamin B Complex in Treating PEG-Asparaginase or Inotuzumab Ozogamicin-Induced Hyperbilirubinemia in Patients With Acute Lymphoblastic LeukemiaTerminatedNCT03564678Phase 2Results posted
• Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic LeukemiaTerminatedNCT03518112Phase 2Results posted
• Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or LymphomaCompletedNCT03096782Phase 2Results posted
• Inotuzumab Ozogamicin in Treating Patients With Relapsed or Refractory CD22 Positive Acute Lymphoblastic LeukemiaTerminatedNCT03094611Phase 2Results posted
• Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid MalignanciesCompletedNCT03056339Phase 1/2Results posted
• Blinatumomab Maintenance Following Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Lymphoblastic LeukemiaCompletedNCT02807883Phase 2Results posted
• Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic LeukemiaTerminatedNCT02420717Phase 2Results posted
• Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaTerminatedNCT02419469Phase 2Results posted
• Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CMLCompletedNCT02311998Phase 1/2Results posted
• Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic LeukemiaCompletedNCT02199184Phase 2Results posted
• Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine ConditioningCompletedNCT01572662Phase 2Results posted
• Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaCompletedNCT01363128Phase 2Results posted
• Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic LeukemiaCompletedNCT01319981Phase 2Results posted
• CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)CompletedNCT01134575Phase 2Results posted
• Procrit Versus No Procrit in Acute Lymphocytic Leukemia, Lymphoblastic Lymphoma, or Burkitt's Undergoing Induction/Consolidation ChemotherapyCompletedNCT01099202Not applicableResults posted
• Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell TransplantationCompletedNCT00990249Phase 2Results posted
• RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic LeukemiaCompletedNCT00968253Phase 1/2Results posted
• Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL)TerminatedNCT00941928Phase 2Results posted
• Methotrexate, Vincristine, Pegylated L-Asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic Leukemia (ALL) SalvageCompletedNCT00905034Phase 2Results posted
• Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia SalvageCompletedNCT00890656Phase 2Results posted
• Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic LymphomaCompletedNCT00866749Phase 2Results posted
• Bendamustine in Acute Leukemia and MDSTerminatedNCT00790855Phase 1/2Results posted
• INCB018424 in Patients With Advanced Hematologic MalignanciesCompletedNCT00674479Phase 2Results posted
• Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic LeukemiaCompletedNCT00671658Phase 2Results posted
• Erwinase Study in Patients With Acute Lymphoblastic LeukemiaCompletedNCT00506597Not applicableResults posted
• Effect of Tight Control of Blood Glucose During Hyper-CVAD Chemotherapy For Acute Lymphocytic Leukemia (ALL)TerminatedNCT00500240Phase 3Results posted
• Rituximab to the Preparative Regimen of Etoposide and Total Body Irradiation in Acute Lymphoblastic LeukemiaCompletedNCT00427791Phase 2Results posted
• Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia PatientsCompletedNCT00412243Phase 1/2Results posted
• Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.CompletedNCT00390793Phase 2Results posted
• Randomized Double Cord Blood Transplant StudyCompletedNCT00067002Phase 2Results posted
• Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic LeukemiaCompletedNCT00038610Phase 2Results posted
• A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic LeukemiaWithdrawnNCT07428486Phase 1
• Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Disease Positive B-cell Acute Lymphoblastic LeukemiaSuspendedNCT07192237Phase 2
• A Phase I Study of Mosunetuzumab for Relapsed or Refractory B-Cell Acute Lymphoblastic LeukemiaWithdrawnNCT05961696Phase 1
• STI-6129 CD38 ADC for the Treatment of Patients With Relapsed or Refractory Systemic ALL AmyloidosisWithdrawnNCT05519527Phase 1
• A Phase II Randomized Controlled Trial to Determine the Efficacy of an auGmented reAlity gaMe in pediatrIc caNcer Patients Who Are Opioid Naïve Undergoing Surgery to Reduce Postoperative Opioid Use (GAMING-ON Study)CompletedNCT05466994Phase 2
• A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic LeukemiaTerminatedNCT05268003Phase 2
• Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory LeukemiaTerminatedNCT04526795Phase 1
• Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or LymphomaWithdrawnNCT04029038Phase 1/2
• Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell TransplantActive, not recruitingNCT03622788Phase 1/2
• CD19-Specific T Cells Post AlloSCTTerminatedNCT03579888Phase 1
• Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual DiseaseActive, not recruitingNCT03441061Phase 2
• Trial Evaluating the Efficacy and Safety of Daratumumab in Subjects With Relapsed/Refractory B-cell or T-cell Precursor Acute Lymphoblastic Leukemia (ALL)WithdrawnNCT03207542Phase 2
• Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic LeukemiaActive, not recruitingNCT03147612Phase 2
• Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory LeukemiaActive, not recruitingNCT03132454Phase 1
• Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT02960646Phase 1
• Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell TransplantActive, not recruitingNCT02861417Phase 2
• CD19-Specific T-cells in Treating Patients With Advanced Lymphoid MalignanciesCompletedNCT02529813Phase 1
• ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic SyndromeTerminatedNCT02392572Phase 1/2
• Infusion of Allogeneic, 3rd Party CD19-specific T CellsWithdrawnNCT02274506Phase 1
• Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell TransplantCompletedNCT02083250Phase 1
• IPI-145 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)WithdrawnNCT02028039Phase 2
• Study of Moxetumomab Pasudotox in Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)TerminatedNCT01891981Phase 1
• Bendamustine in Acute Lymphoblastic Leukemia/Lymphoma (ALL)WithdrawnNCT01649622Phase 2
• NK Cells in Cord Blood TransplantationStatus unknownNCT01619761Phase 1
• Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic LeukemiaActive, not recruitingNCT01424982Phase 2
• A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL)CompletedNCT00349596Phase 1
• RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell LymphomaCompletedNCT00081874Phase 1/2
• Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid MalignanciesTerminatedNCT00038883Not applicable
• Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS)TerminatedNCT00038805Phase 2/3